株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

経皮ドラッグデリバリ:医療機器のパイプライン評価

Transdermal Drug Delivery Devices - Medical Devices Pipeline Assessment, 2017

発行 GlobalData 商品コード 408769
出版日 ページ情報 英文 520 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
経皮ドラッグデリバリ:医療機器のパイプライン評価 Transdermal Drug Delivery Devices - Medical Devices Pipeline Assessment, 2017
出版日: 2017年10月11日 ページ情報: 英文 520 Pages
概要

当レポートでは、世界の経皮ドラッグデリバリ市場における、主要なパイプライン製品 (医療機器) とその治験の進行状況について調査すると共に、製品特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (資本取引・事業提携など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 経皮ドラッグデリバリの概要

第3章 現在治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:セグメント別
  • パイプライン製品:領域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • 現在進行中の治験

第4章 経皮ドラッグデリバリ:各企業で現在治験中のパイプライン製品

  • 経皮ドラッグデリバリの企業:治験段階別のパイプライン製品
  • 経皮ドラッグデリバリ:治験段階別のパイプライン製品

第5章 経皮ドラッグデリバリの企業・製品の概要

  • 3M Company
  • Aequus Pharmaceuticals Inc
  • Agile Therapeutics Inc
  • Allergan Plc
  • Alliqua BioMedical Inc
  • Altea Therapeutics Corporation (Inactive)
  • Anterios Inc
  • Apogee Technology Inc
  • Avro Life Sciences
  • Axxia Pharmaceuticals, LLC
  • Burke Pharmaceuticals LLC
  • Carbylan Therapeutics Inc
  • Cerimon Pharmaceuticals, Inc. (Inactive)
  • Corium International Inc
  • DBV Technologies SA
  • Dermisonics, Inc.
  • Dharma Therapeutics, Inc. (Inactive)
  • DURECT Corp
  • Echo Therapeutics Inc
  • Exploit Technologies Pte Ltd
  • Extend Biosciences Inc
  • EyeGate Pharmaceuticals Inc
  • Fe3 Medical Inc
  • FluGen Inc
  • French National Institute of Health and Medical Research
  • 久光製薬
  • ImmuPatch
  • Imperial College London
  • Indian Institute of Technology Bombay
  • Intercell AG (Inactive)
  • Interstitial NS
  • Isis Biopolymer, Inc.
  • Janisys
  • Massachusetts Institute of Technology
  • Meda AB
  • Medherant Ltd
  • メドレックス
  • mesoestetic USA Inc
  • Micropoint Technologies Pte Ltd
  • National Taiwan Ocean University
  • NeuroDerm Ltd
  • 日東電工
  • North Carolina State University
  • Novosanis NV
  • Nuvo Pharmaceuticals Inc
  • Old Dominion University
  • Pantec Biosolutions AG
  • Phosphagenics Ltd
  • Purdue University
  • Radius Health Inc
  • Ratio Inc
  • Scilex Ltd
  • Sensile Medical AG
  • Skinject Inc
  • ソレイジア・ファーマ
  • Sparsha Pharma International Pvt Ltd
  • Sparsha Pharma USA Inc
  • Stanford University
  • 大日本住友製薬
  • Syntropharma Ltd
  • 帝國製薬
  • tesa Labtec GmbH
  • Teva Pharmaceutical Industries Ltd
  • TheraJect Inc
  • TheraSolve NV
  • Theratech, Inc.
  • Titan Pharmaceuticals Inc
  • Transcu Group Limited (Inactive)
  • Transdermal Delivery Solutions Corp
  • TransPharma Medical Ltd
  • Transport Pharmaceuticals Inc
  • Univec, Inc. (Inactive)
  • University of Illinois at Chicago
  • University of Toronto
  • Vyteris, Inc. (Inactive)
  • Zambon Italia Srl
  • Z-Cube Srl
  • Zosano Pharma Corp
  • Zynerba Pharmaceuticals Inc

第6章 経皮ドラッグデリバリ市場:昨今の動向

第7章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0482EPD

GlobalData's Medical Devices sector report, "Transdermal Drug Delivery Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Transdermal Drug Delivery Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transdermal Drug Delivery Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Transdermal Drug Delivery Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transdermal Drug Delivery Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transdermal Drug Delivery Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 11
  • 1.2 List of Figures 19

2 Introduction 20

  • 2.1 Transdermal Drug Delivery Devices Overview 20

3 Products under Development 21

  • 3.1 Transdermal Drug Delivery Devices - Pipeline Products by Stage of Development 21
  • 3.2 Transdermal Drug Delivery Devices - Pipeline Products by Segment 22
  • 3.3 Transdermal Drug Delivery Devices - Pipeline Products by Territory 23
  • 3.4 Transdermal Drug Delivery Devices - Pipeline Products by Regulatory Path 24
  • 3.5 Transdermal Drug Delivery Devices - Pipeline Products by Estimated Approval Date 25
  • 3.6 Transdermal Drug Delivery Devices - Ongoing Clinical Trials 26

4 Transdermal Drug Delivery Devices - Pipeline Products under Development by Companies 27

  • 4.1 Transdermal Drug Delivery Devices Companies - Pipeline Products by Stage of Development 27
  • 4.2 Transdermal Drug Delivery Devices - Pipeline Products by Stage of Development 31

5 Transdermal Drug Delivery Devices Companies and Product Overview 35

  • 5.1 3M Co Company Overview 35
  • 5.2 4P Therapeutics LLC Company Overview 36
  • 5.3 Actuated Medical Inc Company Overview 37
  • 5.4 Aequus Pharmaceuticals Inc Company Overview 38
  • 5.5 Agile Therapeutics Inc Company Overview 43
  • 5.6 Allergan Plc Company Overview 47
  • 5.7 Alliqua BioMedical Inc Company Overview 49
  • 5.8 Altea Therapeutics Corporation (Inactive) Company Overview 50
  • 5.9 AMW GmbH Company Overview 53
  • 5.10 Apogee Technology Inc Company Overview 55
  • 5.11 Apricus Biosciences Inc Company Overview 56
  • 5.12 Aquavit Pharmaceuticals Inc Company Overview 58
  • 5.13 AstraZeneca Plc Company Overview 61
  • 5.14 Avro Life Sciences Company Overview 62
  • 5.15 Axxia Pharmaceuticals, LLC Company Overview 63
  • 5.16 Burke Pharmaceuticals LLC Company Overview 64
  • 5.17 CB Scientific Inc. Company Overview 66
  • 5.18 Cerimon Pharmaceuticals, Inc. (Inactive) Company Overview 67
  • 5.19 Chrono Therapeutics Inc Company Overview 68
  • 5.20 Corium International Inc Company Overview 69
  • 5.21 DBV Technologies SA Company Overview 76
  • 5.22 Dermisonics, Inc. Company Overview 80
  • 5.23 Dharma Therapeutics, Inc. (Inactive) Company Overview 81
  • 5.24 DURECT Corp Company Overview 82
  • 5.25 Echo Therapeutics Inc Company Overview 83
  • 5.26 Emplicure AB Company Overview 84
  • 5.27 Endo International Plc Company Overview 86
  • 5.28 Extend Biosciences Inc Company Overview 87
  • 5.29 EyeGate Pharmaceuticals Inc Company Overview 88
  • 5.30 Fe3 Medical Inc Company Overview 91
  • 5.31 FluGen Inc Company Overview 92
  • 5.32 French National Institute of Health and Medical Research Company Overview 93
  • 5.33 Hisamitsu Pharmaceutical Co Inc Company Overview 94
  • 5.34 ImmuPatch Company Overview 104
  • 5.35 Imperial College London Company Overview 106
  • 5.36 Indian Institute of Science Company Overview 107
  • 5.37 Indian Institute of Technology Bombay Company Overview 108
  • 5.38 InMed Pharmaceuticals Inc Company Overview 109
  • 5.39 Institute of Materials Research & Engineering Company Overview 110
  • 5.40 Intercell AG (Inactive) Company Overview 111
  • 5.41 Interstitial NS Company Overview 112
  • 5.42 Isis Biopolymer, Inc. Company Overview 113
  • 5.43 Janisys Company Overview 117
  • 5.44 Kalvista Pharmaceuticals Inc Company Overview 118
  • 5.45 KTH Royal Institute of Technology Company Overview 119
  • 5.46 Kyowa Hakko Kirin Co Ltd Company Overview 120
  • 5.47 Massachusetts Institute of Technology Company Overview 121
  • 5.48 Mayne Pharma International Pty Ltd Company Overview 122
  • 5.49 Medherant Ltd Company Overview 123
  • 5.50 MEDRx Co Ltd Company Overview 124
  • 5.51 mesoestetic USA Inc Company Overview 129
  • 5.52 Microdermics Inc Company Overview 130
  • 5.53 Micropoint Technologies Pte Ltd Company Overview 131
  • 5.54 National Taiwan Ocean University Company Overview 132
  • 5.55 Nemaura Pharma Ltd Company Overview 133
  • 5.56 NeuroDerm Ltd Company Overview 135
  • 5.57 Nitto Denko Corp Company Overview 137
  • 5.58 North Carolina State University Company Overview 139
  • 5.59 Novosanis NV Company Overview 141
  • 5.60 Nuvo Pharmaceuticals Inc Company Overview 144
  • 5.61 Old Dominion University Company Overview 145
  • 5.62 Pain Therapeutics Inc Company Overview 146
  • 5.63 Pantec Biosolutions AG Company Overview 147
  • 5.64 Phosphagenics Ltd Company Overview 148
  • 5.65 Purdue University Company Overview 153
  • 5.66 Radius Health Inc Company Overview 154
  • 5.67 Ratio Inc Company Overview 155
  • 5.68 Scilex Ltd Company Overview 156
  • 5.69 Sensile Medical AG Company Overview 158
  • 5.70 Skinject Inc Company Overview 159
  • 5.71 Sparsha Pharma International Pvt Ltd Company Overview 160
  • 5.72 Sparsha Pharma USA Inc Company Overview 162
  • 5.73 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview 163
  • 5.74 Stanford University Company Overview 164
  • 5.75 Sumitomo Dainippon Pharma Co Ltd Company Overview 165
  • 5.76 Sun Pharma Advanced Research Company Ltd Company Overview 166
  • 5.77 Syntropharma Ltd Company Overview 167
  • 5.78 Taho Pharmaceuticals Ltd Company Overview 168
  • 5.79 Teikoku Pharma USA Inc Company Overview 170
  • 5.80 Teikoku Seiyaku Co Ltd Company Overview 173
  • 5.81 tesa Labtec GmbH Company Overview 174
  • 5.82 Teva Pharmaceutical Industries Ltd Company Overview 175
  • 5.83 The Sheikh Zayed Institute for Pediatric Surgical Innovation Company Overview 176
  • 5.84 TheraJect Inc Company Overview 177
  • 5.85 TheraSolve NV Company Overview 179
  • 5.86 Theratech, Inc. Company Overview 180
  • 5.87 Titan Pharmaceuticals Inc Company Overview 181
  • 5.88 Transcu Group Limited (Inactive) Company Overview 187
  • 5.89 Transdermal Delivery Solutions Corp Company Overview 188
  • 5.90 TransPharma Medical Ltd (Inactive) Company Overview 191
  • 5.91 Transport Pharmaceuticals Inc Company Overview 193
  • 5.92 TSRL Inc Company Overview 194
  • 5.93 Univec, Inc. (Inactive) Company Overview 195
  • 5.94 University of Illinois at Chicago Company Overview 198
  • 5.95 University of Toronto Company Overview 199
  • 5.96 Vyteris, Inc. (Inactive) Company Overview 200
  • 5.97 Yale University Company Overview 201
  • 5.98 Zambon Italia Srl Company Overview 202
  • 5.99 Z-Cube Srl Company Overview 203
  • 5.100 Zosano Pharma Corp Company Overview 204
  • 5.101 Zynerba Pharmaceuticals Inc Company Overview 206

6 Transdermal Drug Delivery Devices - Recent Developments 210

  • 6.1 Sep 20, 2017: DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development 210
  • 6.2 Sep 19, 2017: FluGen Announces Expanded Role for Clinical Advisory Board: Dr. Robert Belshe to Chair 210
  • 6.3 Sep 18, 2017: National Institute on Drug Abuse Awards Pain Therapeutics $2.2 Million Grant 211
  • 6.4 Sep 14, 2017: Intarcia and Numab Reach Key Milestone with Selection of Multi-specific Development Candidate for Autoimmune Disease 212
  • 6.5 Sep 12, 2017: FDA Acknowledges Receipt Of Sorrento Therapeutics NDA For ZTlido; PDUFA Date Set For February 28, 2018 213
  • 6.6 Sep 11, 2017: Teva Names Kare Schultz as President and Chief Executive Officer 213
  • 6.7 Sep 11, 2017: The Allergan Foundation to Donate $150,000 to Support Hurricane Irma Relief Efforts 214
  • 6.8 Sep 07, 2017: Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch 214
  • 6.9 Sep 07, 2017: Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine 215
  • 6.10 Sep 07, 2017: Lilly Takes Steps To Streamline Business, Invest In New Medicines And Drive Growth 216
  • 6.11 Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors 217
  • 6.12 Sep 05, 2017: FluGen Announces C. Boyd Clarke Has Been Named Executive Chairman 217
  • 6.13 Sep 01, 2017: Start of MRX-4TZT Phase I a' Clinical Trial in the United States 218
  • 6.14 Aug 31, 2017: Kyowa Hakko Kirin: Announcement of submission of supplemental new drug application for the addition of a new 0.5mg dose of the transdermal, long-acting pain relief patch FENTOS TAPE 218
  • 6.15 Aug 31, 2017: Aquavit's iMicrotox (IMX-001) Study Receives IRB Approval 219
  • 6.16 Aug 30, 2017: GSK responds to UK Life Sciences Industrial Strategy 219
  • 6.17 Aug 29, 2017: Sorrento Therapeutics Submits NDA For ZTlidoNext-Generation Lidocaine Patch 219
  • 6.18 Aug 29, 2017: Aequus Provides Second Quarter 2017 Operational Highlights 220
  • 6.19 Aug 24, 2017: Titan Pharmaceuticals Receives FDA Clearance To Begin Clinical Study Of Parkinson's Disease Treatment 222
  • 6.20 Aug 24, 2017: Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole 222
  • 6.21 Aug 23, 2017: Lannett Reports Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Provides Guidance For Fiscal 2018 224
  • 6.22 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 225
  • 6.23 Aug 11, 2017: SteadyMed Reports Second Quarter 2017 Financial Results and Provides Corporate Update 227
  • 6.24 Aug 11, 2017: Valeritas Reports Second Quarter 2017 Financial Results 228
  • 6.25 Aug 10, 2017: Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update 230
  • 6.26 Aug 10, 2017: Alliqua BioMedical Reports Second Quarter of Fiscal Year 2017 Financial Results 231
  • 6.27 Aug 09, 2017: The Medicines Company Reports Second Quarter 2017 Business and Financial Results 233
  • 6.28 Aug 08, 2017: DURECT Announces Second Quarter 2017 Financial Results and Provides Corporate Update 235
  • 6.29 Aug 08, 2017: Lannett Announces Preliminary Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Comments On Fiscal 2018 Outlook 237
  • 6.30 Aug 08, 2017: Antares Pharma Reports Second Quarter 2017 Operating And Financial Results 238
  • 6.31 Aug 07, 2017: EyeGate Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 240
  • 6.32 Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 241
  • 6.33 Aug 03, 2017: Allergan Reports Continued Strong Execution in Second Quarter 2017 with 9% Increase in GAAP Net Revenues to $4.0 Billion 243
  • 6.34 Aug 03, 2017: Revance Releases Second Quarter 2017 Results 248
  • 6.35 Aug 03, 2017: Corium Reports Recent Corporate Highlights and Financial Results for Third Quarter Fiscal 2017 249
  • 6.36 Aug 01, 2017: EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for Cataract Surgery 250
  • 6.37 Jul 31, 2017: Perrigo Announces Launch Of AB Rated Generic Version Of Transderm Scop 1.5 mg 251
  • 6.38 Jul 31, 2017: SteadyMed Appoints Jeff Myers M.D. Ph.D. Vice President of Medical Affairs 251
  • 6.39 Jul 28, 2017: Agile Therapeutics Reports Second Quarter 2017 Financial Results 252
  • 6.40 Jul 27, 2017: Agile Therapeutics Announces FDA Acceptance Of The NDA Resubmission Of Twirla 253
  • 6.41 Jul 27, 2017: UCB with a strong first half year 2017 - giving rise to the financial outlook for 2017 254
  • 6.42 Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group 256
  • 6.43 Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK 262
  • 6.44 Jul 25, 2017: Lilly Reports Second-Quarter Results 262
  • 6.45 Jul 25, 2017: 3M Delivers Second-Quarter Sales of $7.8 Billion and Earnings of $2.58 per Share; Company Updates Its 2017 Outlook 267
  • 6.46 Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 269
  • 6.47 Jul 21, 2017: GSK announces Board and Committee changes 269
  • 6.48 Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 270
  • 6.49 Jul 18, 2017: Corium Presents Clinical Results from Pilot Bioequivalence Study of Corplex Donepezil Transdermal System at Alzheimer's Association International Conference 2017 270
  • 6.50 Jul 17, 2017: Lannett Appoints Samuel H. Israel As General Counsel 271
  • 6.51 Jul 13, 2017: Camurus: Interim report January-June 2017 271
  • 6.52 Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 273
  • 6.53 Jul 06, 2017: Corium to Present Clinical Results from Pilot Bioequivalence Study of Once-weekly Corplex Donepezil Transdermal System at Alzheimer's Association International Conference 2017 273
  • 6.54 Jul 05, 2017: Aequus Receives Approval from Health Canada to Initiate Proof of Concept Clinical Trial of Anti-Nausea Patch 274
  • 6.55 Jul 04, 2017: Sumitomo Dainippon Pharma Announces Change in Name of Consolidated Subsidiary Based in U.S. 274

7 Appendix 515

  • 7.1 Methodology 515
  • 7.2 About GlobalData 518
  • 7.3 Contact Us 518
  • 7.4 Disclaimer 518

List of Tables

1.1 List of Tables

  • Table 1: Transdermal Drug Delivery Devices - Pipeline Products by Stage of Development 23
  • Table 2: Transdermal Drug Delivery Devices - Pipeline Products by Segment 24
  • Table 3: Transdermal Drug Delivery Devices - Pipeline Products by Territory 25
  • Table 4: Transdermal Drug Delivery Devices - Pipeline Products by Regulatory Path 26
  • Table 5: Transdermal Drug Delivery Devices - Pipeline Products by Estimated Approval Date 27
  • Table 6: Transdermal Drug Delivery Devices - Ongoing Clinical Trials 28
  • Table 7: Transdermal Drug Delivery Devices Companies - Pipeline Products by Stage of Development 29
  • Table 8: Transdermal Drug Delivery Devices - Pipeline Products by Stage of Development 33
  • Table 9: 3M Co Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 10: 3M Hollow Microstructured Transdermal System - Product Status 37
  • Table 11: 3M Hollow Microstructured Transdermal System - Product Description 37
  • Table 12: 4P Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 13: Transdermal FSH Patch - Product Status 38
  • Table 14: Transdermal FSH Patch - Product Description 38
  • Table 15: Actuated Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 16: GentleDispense System - Product Status 39
  • Table 17: GentleDispense System - Product Description 39
  • Table 18: Aequus Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 19: AQS1301 - Product Status 40
  • Table 20: AQS1301 - Product Description 40
  • Table 21: AQS1302 - Product Status 41
  • Table 22: AQS1302 - Product Description 41
  • Table 23: AQS1303 - Product Status 41
  • Table 24: AQS1303 - Product Description 42
  • Table 25: AQS1304 - Product Status 42
  • Table 26: AQS1304 - Product Description 42
  • Table 27: Aequus Pharmaceuticals Inc - Ongoing Clinical Trials Overview 43
  • Table 28: AQS1301 - Phase Ia Study of AQS-1301 in Healthy Subjects 44
  • Table 29: Agile Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 30: AG200-ER Patch - Product Status 45
  • Table 31: AG200-ER Patch - Product Description 46
  • Table 32: AG200-SP Patch - Product Status 46
  • Table 33: AG200-SP Patch - Product Description 47
  • Table 34: AG890 Patch - Product Status 47
  • Table 35: AG890 Patch - Product Description 47
  • Table 36: Twirla (AG200-15) - Product Status 48
  • Table 37: Twirla (AG200-15) - Product Description 48
  • Table 38: Allergan Plc Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 39: Nanotechnology-Based Transdermal Delivery System - Product Status 49
  • Table 40: Nanotechnology-Based Transdermal Delivery System - Product Description 49
  • Table 41: Norethindrone Transdermal Delivery System - Product Status 50
  • Table 42: Norethindrone Transdermal Delivery System - Product Description 50
  • Table 43: Alliqua BioMedical Inc Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 44: PHN Patch - Product Status 51
  • Table 45: PHN Patch - Product Description 51
  • Table 46: Altea Therapeutics Corporation (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 47: PassPort Exenatide Transdermal Delivery System - Product Status 52
  • Table 48: PassPort Exenatide Transdermal Delivery System - Product Description 52
  • Table 49: Transdermal Enoxaparin Sodium Patch - Product Status 53
  • Table 50: Transdermal Enoxaparin Sodium Patch - Product Description 53
  • Table 51: Transdermal Fentanyl Citrate Patch - Product Status 53
  • Table 52: Transdermal Fentanyl Citrate Patch - Product Description 54
  • Table 53: Transdermal Protein Patch - Product Status 54
  • Table 54: Transdermal Protein Patch - Product Description 54
  • Table 55: AMW GmbH Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 56: Rotigotine Patch - Product Status 55
  • Table 57: Rotigotine Patch - Product Description 55
  • Table 58: Transdermal Patch - Breast Cancer - Product Status 56
  • Table 59: Transdermal Patch - Breast Cancer - Product Description 56
  • Table 60: Apogee Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 61: PyraDerm - Product Status 57
  • Table 62: PyraDerm - Product Description 57
  • Table 63: Apricus Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 64: Vitaros - Product Status 58
  • Table 65: Vitaros - Product Description 59
  • Table 66: Aquavit Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 67: iMicrotox - Product Status 60
  • Table 68: iMicrotox - Product Description 60
  • Table 69: Aquavit Pharmaceuticals Inc - Ongoing Clinical Trials Overview 61
  • Table 70: iMicrotox - Efficacy of iMicrotox to Treat Mild-to-moderate Peri-orbital Rhytids 62
  • Table 71: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 72: EMLA Patch - Product Status 63
  • Table 73: EMLA Patch - Product Description 63
  • Table 74: Avro Life Sciences Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 75: Transdermal Drug Delivery Patch - Product Status 64
  • Table 76: Transdermal Drug Delivery Patch - Product Description 64
  • Table 77: Axxia Pharmaceuticals, LLC Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 78: Drug Delivery Implant - Product Status 65
  • Table 79: Drug Delivery Implant - Product Description 65
  • Table 80: Burke Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 81: BLU402 Hydrogel Patch Wart Kit - Product Status 66
  • Table 82: BLU402 Hydrogel Patch Wart Kit - Product Description 66
  • Table 83: Drug Delivery Patch - Product Status 67
  • Table 84: Drug Delivery Patch - Product Description 67
  • Table 85: CB Scientific Inc. Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 86: Pain-Patch - Product Status 68
  • Table 87: Pain-Patch - Product Description 68
  • Table 88: Cerimon Pharmaceuticals, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 89: Topical Diclofenac Patch - Product Status 69
  • Table 90: Topical Diclofenac Patch - Product Description 69
  • Table 91: Chrono Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 92: Biologically-Timed Drug Delivery Device - Product Status 70
  • Table 93: Biologically-Timed Drug Delivery Device - Product Description 70
  • Table 94: Corium International Inc Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 95: Corplex Donepezil Transdermal System - Product Status 71
  • Table 96: Corplex Donepezil Transdermal System - Product Description 72
  • Table 97: Corplex Memantine Transdermal System - Product Status 72
  • Table 98: Corplex Memantine Transdermal System - Product Description 72
  • Table 99: Corplex Ropinirole Transdermal System - Product Status 73
  • Table 100: Corplex Ropinirole Transdermal System - Product Description 73
  • Table 101: MicroCor Transdermal System - Product Status 73
  • Table 102: MicroCor Transdermal System - Product Description 74
  • Table 103: MicroCor Zolmitriptan System - Product Status 74
  • Table 104: MicroCor Zolmitriptan System - Product Description 74
  • Table 105: MicroJet - Product Status 75
  • Table 106: MicroJet - Product Description 75
  • Table 107: Corium International Inc - Ongoing Clinical Trials Overview 76
  • Table 108: Corplex Donepezil Transdermal System - A Phase I Crossover Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of Two Formulations of a 7-day Application Donepezil Transdermal Delivery System (TDS) Compared to Oral Administration of Aricept in Healthy Volunteers 77
  • Table 109: Corplex Donepezil Transdermal System - A Study to Assess the Steady-state Bioequivalence of Once-weekly Corplex Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept 77
  • Table 110: Corplex Donepezil Transdermal System - Phase 1 Clinical Trial of Corplex Donepezil Transdermal System for the Treatment of Alzheimer's Disease 77
  • Table 111: DBV Technologies SA Pipeline Products & Ongoing Clinical Trials Overview 78
  • Table 112: Viaskin Peanut - Product Status 78
  • Table 113: Viaskin Peanut - Product Description 78
  • Table 114: DBV Technologies SA - Ongoing Clinical Trials Overview 79
  • Table 115: Viaskin Peanut - A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy with Viaskin Peanut in Peanut-allergic Children 80
  • Table 116: Viaskin Peanut - A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age 80
  • Table 117: Viaskin Peanut - Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut 80
  • Table 118: Viaskin Peanut - Safety Study of Viaskin Peanut to Treat Peanut Allergy (REALISE) 81
  • Table 119: Dermisonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 82
  • Table 120: U-Strip - Product Status 82
  • Table 121: U-Strip - Product Description 82
  • Table 122: Dharma Therapeutics, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 83
  • Table 123: Iontophoretic Drug Delivery Patch - Product Status 83
  • Table 124: Iontophoretic Drug Delivery Patch - Product Description 83
  • Table 125: DURECT Corp Pipeline Products & Ongoing Clinical Trials Overview 84
  • Table 126: Eladur - Product Status 84
  • Table 127: Eladur - Product Description 84
  • Table 128: Echo Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 85
  • Table 129: Prelude SkinPrep System - Product Status 85
  • Table 130: Prelude SkinPrep System - Product Description 85
  • Table 131: Emplicure AB Pipeline Products & Ongoing Clinical Trials Overview 86
  • Table 132: Micro-needle Patch - Product Status 86
  • Table 133: Micro-needle Patch - Product Description 86
  • Table 134: Tamper Resistant Patch - Product Status 87
  • Table 135: Tamper Resistant Patch - Product Description 87
  • Table 136: Endo International Plc Pipeline Products & Ongoing Clinical Trials Overview 88
  • Table 137: Rivastigmine Patch - Product Status 88
  • Table 138: Rivastigmine Patch - Product Description 88
  • Table 139: Extend Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 89
  • Table 140: Non-Invasive Needle-Free Skin Patch - Product Status 89
  • Table 141: Non-Invasive Needle-Free Skin Patch - Product Description 89
  • Table 142: EyeGate Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 90
  • Table 143: EyeGate II Delivery System - Product Status 90
  • Table 144: EyeGate II Delivery System - Product Description 90
  • Table 145: EyeGate Pharmaceuticals Inc - Ongoing Clinical Trials Overview 91
  • Table 146: EyeGate II Delivery System - A Prospective, Multi-center, Randomized, Double-masked, Positive Controlled, Phase III Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients with Non-infectious Anterior Segment Uveitis 92
  • Table 147: EyeGate II Delivery System - Multi-center, Double-masked, Randomized, Placebo-controlled Phase IIb Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Having Undergone Cataract Surgery with Implantation of a Posterior Chamber Intraocular Lens (IOL) 92
  • Table 148: Fe3 Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 93
  • Table 149: Iron Supplement Patch - Product Status 93
  • Table 150: Iron Supplement Patch - Product Description 93
  • Table 151: FluGen Inc Pipeline Products & Ongoing Clinical Trials Overview 94
  • Table 152: FLUGEN 101.2 Microneedle-based Delivery Device - Product Status 94
  • Table 153: FLUGEN 101.2 Microneedle-based Delivery Device - Product Description 94

List of Figures

1.2 List of Figures

  • Figure 1: Transdermal Drug Delivery Devices - Pipeline Products by Stage of Development 23
  • Figure 2: Transdermal Drug Delivery Devices - Pipeline Products by Segment 24
  • Figure 3: Transdermal Drug Delivery Devices - Pipeline Products by Territory 25
  • Figure 4: Transdermal Drug Delivery Devices - Pipeline Products by Regulatory Path 26
  • Figure 5: Transdermal Drug Delivery Devices - Pipeline Products by Estimated Approval Date 27
  • Figure 6: Transdermal Drug Delivery Devices - Ongoing Clinical Trials 28
Back to Top